MetaADEDB 2.0 @ LMMD
Fluticasone/salmeterol
(YYAZJTUGSQOFHG-RZFXJYHSSA-N)
Structure
SMILES
OCc1cc(ccc1O)C(CNCCCCCCOCCCCc1ccccc1)O.FCSC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2C[C@@H](C2=CC(=O)C=C[C@]12C)F)F
Molecular Formula:
C50H68F3NO9S
Molecular Weight:
916.136
Log P:
8.9283
Hydrogen Bond Acceptor:
11
Hydrogen Bond Donor:
5
TPSA:
187.92
CAS Number(s):
N/A
Synonym(s)
1.
Fluticasone/salmeterol
External Link(s)
PubChem Compound9811567
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1AsthmaFAERS: 6US FAERS
2Angina PectorisFAERS: 4US FAERS
3AstheniaFAERS: 4US FAERS
4TachycardiaFAERS: 4SIDER
US FAERS
5Drug DependenceFAERS: 3US FAERS
6PneumoniaFAERS: 3SIDER
US FAERS
7AngioedemaFAERS: 2SIDER
US FAERS
8Blood creatine phosphokinase increasedFAERS: 2US FAERS
9DisabilityFAERS: 2US FAERS
10DysphoniaFAERS: 2SIDER
US FAERS
11Enamel anomalyFAERS: 2US FAERS
12InfectionFAERS: 2SIDER
US FAERS
13Lip swellingFAERS: 2US FAERS
14MyalgiaFAERS: 2US FAERS
15Pathological fractureFAERS: 2US FAERS
16Product quality issueFAERS: 2US FAERS
17Respiratory distressFAERS: 2US FAERS
18RhabdomyolysisFAERS: 2US FAERS
19TuberculosisFAERS: 2US FAERS
20Upper airway obstructionFAERS: 2US FAERS
21Accidental overdoseFAERS: 1US FAERS
22Adverse eventFAERS: 1US FAERS
23AgitationFAERS: 1SIDER
US FAERS
24AnxietyFAERS: 1SIDER
US FAERS
25ArthralgiaFAERS: 1SIDER
US FAERS
26BronchospasmFAERS: 1SIDER
US FAERS
27CataractFAERS: 1SIDER
US FAERS
28Cerebrovascular accidentFAERS: 1US FAERS
29Chest discomfortFAERS: 1US FAERS
30Choking sensationFAERS: 1US FAERS
31DizzinessFAERS: 1US FAERS
32Drug exposure during pregnancyFAERS: 1US FAERS
33Drug exposure via breast milkFAERS: 1US FAERS
34Drug ineffectiveFAERS: 1US FAERS
35EpiglottitisFAERS: 1US FAERS
36EpilepsyFAERS: 1US FAERS
37Expired drug administeredFAERS: 1US FAERS
38Gingival HypertrophyFAERS: 1US FAERS
39HeadacheFAERS: 1SIDER
US FAERS
40HypersensitivityFAERS: 1SIDER
US FAERS
41HyperthyroidismFAERS: 1US FAERS
42HypertrophyFAERS: 1US FAERS
43Macular degenerationFAERS: 1US FAERS
44MalaiseFAERS: 1US FAERS
45Mouth swellingFAERS: 1US FAERS
46Oral fungal infectionFAERS: 1US FAERS
47ParesisFAERS: 1US FAERS
48Product substitution issueFAERS: 1US FAERS
49Product use in unapproved indicationFAERS: 1US FAERS
50Product use issueFAERS: 1US FAERS
51PruritusFAERS: 1US FAERS
52Sense of oppressionFAERS: 1US FAERS
53Suicide attemptFAERS: 1US FAERS
54SyncopeFAERS: 1US FAERS
55Systolic hypertensionFAERS: 1US FAERS
56TremorFAERS: 1SIDER
US FAERS
57Venous ThrombosisFAERS: 1US FAERS
58Visual disturbanceFAERS: 1US FAERS
59Weight decreasedFAERS: 1US FAERS
60Anaphylactic shockSIDER
61Atrial FibrillationSIDER
62Bronchial HyperreactivitySIDER
63Cutaneous hypersensitivitySIDER
64GlaucomaSIDER
65Growth retardationSIDER
66HoarsenessSIDER
67HyperkinesiaSIDER
68InfestationSIDER
69MalnutritionSIDER
70Musculoskeletal discomfortSIDER
71Oral candidiasisSIDER
72Oropharyngeal swellingSIDER
73PalpitationsSIDER
74Supraventricular tachycardiaSIDER
75Throat irritationSIDER
76nervous system disorderSIDER
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120240

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.